NEXT Biometrics Group ASA – Updated key information relating to the rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

Reference is made to the stock exchange announcement published by NEXT Biometrics Group ASA (the "Company"), on 18 March 2026, regarding a contemplated partially underwritten rights issue in the Company, raising gross proceeds of up to NOK 50 million (the "Rights Issue"), and the subsequent stock exchange announcements setting out the key information relating to the Rights Issue published on 18 March 2026 and the updated key information relating to the rights issue published on 9 April 2026. Updated key information relating to the Rights Issue is set out below. Date on which the terms and conditions of the preferential Rights Issue were announced: 18 March 2026.

Date of approval: 19 May 2026 (annual general meeting) Last day including rights: 19 May 2026

Ex-date: 20 May 2026

Record Date: 21 May 2026

Maximum number of new shares to be issued in the Rights Issue: 50,000,000 new shares (the "Offer Shares")

Subscription price: NOK 1

Ratio preferential rights: 4.1715

Subscription ratio: 1:1 (number of new shares in the Company per subscription right)

Manager: Arctic Securities AS

Will the rights be listed: Yes, the Company will apply for listing of the subscription rights on Euronext Oslo Børs.

ISIN for the subscription rights: NO 0013739599 Warrants: The subscribers in the Rights Issue will for every two (2) Offer Shares allocated in the Rights Issue, receive one warrant (Nw.: frittstående tegningsrett) (the “Warrants”) issued by the Company for no additional consideration. The maximum number of Warrants to be issued to the subscribers of Offer Shares in the Rights Issue is 25,000,000 Warrants. Each Warrant will give the holder the right to subscribe for one new share in the Company at an exercise price per share equal to the subscription price in the Rights Issue. Half of the Warrants issued to the subscribers of Offer Shares in the Rights Issue may only be exercised from 17 March 2027 at 09:00 (CET) to 31 March 2027 at 16:30 (CEST), having ISIN NO 0013740621 (the "March 2027 Warrants") (the "March 2027 Warrants Exercise Period"), and half of the Warrants issued to the subscribers of Offer Shares in the Rights Issue may only be exercised from 17 June 2027 at 09:00 (CEST) to 1 July 2027 at 16:30 (CEST), having ISIN NO 0013740720 (the "June 2027 Warrants") (the "June 2027 Warrants Exercise Period", and together with the March 2027 Warrants Exercise Period, the "Exercise Periods"). The Warrants will be transferable and may be admitted to trading on Euronext Oslo Børs.

Other information: Reference is made to the stock exchange announcements published by the Company on 18 March 2026. Completion of the Rights Issue is subject to (i) the completion of a share capital decrease by the reduction of the nominal value of the Company's shares expected on or about 22 May 2026 (the "Share Capital Reduction"), following expiry of a six-week creditor notice period under Section 12-5 of the Norwegian Public Limited Liability Companies Act, and (ii) the Financial Supervisory Authority of Norway having approved, and the Company having published, a prospectus.

For further information, please contact: Ulf Ritsvall (CEO), ulf.ritsvall@nextbiometrics.com Eirik Underthun (CFO), eirik.underthun@nextbiometrics.com

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

IMPORTANT INFORMATION

This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures.

The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made solely to "qualified institutional buyers" as defined in Rule 144A under the Securities Act.

In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression "Prospectus Regulation" means Regulation (EU) 2017/1129 as amended (together with any applicable implementing measures in any Member State.

This communication is only being distributed to and is only directed at persons in the United Kingdom that who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order; or (iii) are other persons to whom it otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons"). Any person who is not a Relevant Person must not act or rely on this Investor Presentation or any of its contents. Any investment or investment activity to which this communication relates is available only for Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.

Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "strategy", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believe that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict, and are beyond their control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not make any guarantee that the assumptions underlying the forward-looking statements in this announcement are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this announcement or any obligation to update or revise the statements in this announcement to reflect subsequent events. You should not place undue reliance on the forward-looking statements in this announcement.

The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement.

This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company.

The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.